Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: J Pharm Sci. 2015 Jul 6;104(10):3426–3439. doi: 10.1002/jps.24551

Figure 3.

Figure 3

(A) Fabricated SAMT-10 IVR (8 wt%), (B) SAMT-10/IQP-0528 IVR (8 wt%/9 wt% respectively), and (C) the commercially available NuvaRing®. (D) DSC scans of placebo PEU, SAMT-10 (8 wt%) single agent in the PEU IVR matrix, IQP-0528 (11 wt%) single agent in the PEU IVR matrix and the combination (8 wt% SAMT-10/9 wt% IQP-0528) in the PEU IVR matrix.